Belimumab: A Guide to Its Use in Systemic Lupus Erythematosus

BioDrugs, 05/08/2012

Belimumab, a fully human recombinant IgG1λ monoclonal antibody that inhibits the binding of soluble B lymphocyte stimulator to B cells, is indicated for the treatment of adult patients with active, autoantibody–positive systemic lupus erythematosus (SLE) with a high degree of disease activity despite receiving standard therapy. In multinational trials, significantly more belimumab recipients than placebo recipients achieved an SLE Responder Index response at 52 weeks.

Print Article Summary Cat 2 CME Report